FROM THE FOUNDATION

All Over the Map

Newly updated to include breast cancer, prostate cancer, and spine procedures, this CHCF-sponsored research shows that practice patterns vary dramatically from place to place.

Medi-Cal Transforms

Medi-Cal is the main source of health insurance for one in five Californians. An updated report gives an overview of the program's key features, describes how the program is evolving, and examines the challenges ahead.

Obama Care in the Second Term

CHCF is a long-time sponsor of the UC Irvine Forecast Conference. A webcast of this year's conference on health policy in President Obama's second term is now available.

Medi-Cal

Reader Comments:

 

Pharmacists Expressing Concern With Medi-Cal Reimbursement Cuts Back to Article >>

2

12/05/2011

James Roache PharmD

CORRECTION TO ABOVE: The rebate for Generic Drugs is much less than for Brand Name Drugs. It is a base rate of 11% of AMP, with no additional rebate. 42 U.S.C. § 1396r-8(c)(3). In contrast, the total rebates due for Brand Name Drugs have typically been within a couple of points of 31% of AMP, a difference of roughly twenty (20) percent. Perhaps Mr. Williams might wish to expand his view as expressed in the Press Telegram whereby he informs us that the State does not receive manufacturer rebates for generic drugs. According to 42 U.S.C. § 1396r-8(c)(3) the State does receive significant rebates on generics.


1

12/05/2011

James Roache PharmD

According to www.medicaid.gov, non-innovator drugs (generics) are rebated to Medicaid at the rate of 13%.


 
 

Sign in or register to share your thoughts on this article.

Click to register for California Healthline